Table 6.
Clinical and biological characteristics of patients with metastatic (n = 25) and non-metastatic (n = 26) sporadic colorectal cancer (sCRC) at diagnosis.
| Variable | Non-metastatic sCRC (n = 26) | Metastatic sCRC (n = 25) | p | Total (n = 51) |
|---|---|---|---|---|
| Age (years)* | 67 (38–83) | 67 (48–79) | NS | 67 (38–83) |
| Gender | ||||
| Female | 7 (27%) | 6 (24%) | NS | 13 (25%) |
| Male | 19 (73%) | 19 (76%) | 38 (75%) | |
| Site of primary tumor | ||||
| Right colon | 9 (35%) | 4 (16%) | 0.020 | 13 (26%) |
| Left colon | 14 (54%) | 10 (40%) | 24 (47%) | |
| Rectum | 3 (11%) | 11 (44%) | 14 (27%) | |
| Histopathological grade | ||||
| Well differentiated | 19 (73%) | 16 (64%) | 35 (69%) | |
| Moderately differentiated | 6 (23%) | 8 (32%) | NS | 14 (27%) |
| Poorly differentiated | 1 (4%) | 1 (4%) | 2 (4%) | |
| Histopathological tumor classification | ||||
| pT1 | 1 (4%) | 0 (0%) | 0.060 | 2 (4%) |
| pT2 | 6 (23%) | 1 (4%) | 6 (11%) | |
| pT3 | 11 (42%) | 19 (76%) | 30 (59%) | |
| pT4 | 8 (31%) | 5 (20%) | 13 (26%) | |
| Lymph node involvement | ||||
| pN0 | 26 (100%) | 9 (36%) | <0.001 | 35 (69%) |
| pN1 | 0 (0%) | 11 (44%) | 11 (21%) | |
| pN2 | 0 (0%) | 5 (20%) | 5 (10%) | |
| TNM stage at diagnosis | ||||
| I | 6 (23%) | 1 (4%) | <0.001 | 7 (14%) |
| IIA | 1 (4%) | 2 (8%) | 3 (6%) | |
| IIB | 17 (65%) | 0 (0%) | 17 (33%) | |
| IIIA | 0 (0%) | 0 (0%) | 0 (0%) | |
| IIIB | 2 (8%) | 1 (4%) | 3 (6%) | |
| IIIC | 0 (0%) | 1 (4%) | 1 (2%) | |
| IV | 0 (0%) | 20 (80%) | 20 (39%) | |
| CEA serum levels* | 4.18 (0.60–17.96) | 269.22 (0.84–1484) | <0.001 | 118.63 (0.60–1484) |
| Number of deaths** | 2 (8%) | 13 (72%) | <0.001 | 15 (34%) |
| OS (months)** | 99.69 (71–124) | 31.61 (7–96) | <0.001 | 71.84 (7–124) |
Results expressed as number of cases (percentage), except * as median (range). **Survival rate calculated for 44 patients (26 non-metastatic and 18 metastatic). CEA: carcinoembryogenic antigen; OS: overall survival; NS, no statistically significant differences found between groups (p > 0.05).